KR20180101452A - 프로리포솜성 테스토스테론 운데카노에이트 제제 - Google Patents

프로리포솜성 테스토스테론 운데카노에이트 제제 Download PDF

Info

Publication number
KR20180101452A
KR20180101452A KR1020187022494A KR20187022494A KR20180101452A KR 20180101452 A KR20180101452 A KR 20180101452A KR 1020187022494 A KR1020187022494 A KR 1020187022494A KR 20187022494 A KR20187022494 A KR 20187022494A KR 20180101452 A KR20180101452 A KR 20180101452A
Authority
KR
South Korea
Prior art keywords
tsx
dosage form
pro
oral dosage
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187022494A
Other languages
English (en)
Korean (ko)
Inventor
구루 베타게리
라마찬드란 티루코테
비란 고우다 카다지
나타라잔 벤카테산
Original Assignee
웨스턴 유니버시티 오브 헬스 사이언시스
테소륵스 파마, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 웨스턴 유니버시티 오브 헬스 사이언시스, 테소륵스 파마, 엘엘씨 filed Critical 웨스턴 유니버시티 오브 헬스 사이언시스
Publication of KR20180101452A publication Critical patent/KR20180101452A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020187022494A 2016-01-08 2017-01-09 프로리포솜성 테스토스테론 운데카노에이트 제제 Withdrawn KR20180101452A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276452P 2016-01-08 2016-01-08
US62/276,452 2016-01-08
US201662394576P 2016-09-14 2016-09-14
US62/394,576 2016-09-14
PCT/US2017/012739 WO2017120592A1 (en) 2016-01-08 2017-01-09 Proliposomal testosterone undecanoate formulations

Publications (1)

Publication Number Publication Date
KR20180101452A true KR20180101452A (ko) 2018-09-12

Family

ID=59274044

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187022494A Withdrawn KR20180101452A (ko) 2016-01-08 2017-01-09 프로리포솜성 테스토스테론 운데카노에이트 제제

Country Status (6)

Country Link
US (1) US20190248830A1 (https=)
EP (1) EP3399965A4 (https=)
JP (1) JP2019501199A (https=)
KR (1) KR20180101452A (https=)
CN (1) CN108601736A (https=)
WO (1) WO2017120592A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604943C (en) 2005-04-15 2013-09-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
ES3006512T3 (en) 2017-11-17 2025-03-18 Evonik Operations Gmbh Process for preparing a coated hard shell capsule
WO2020018974A1 (en) * 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
US20200197412A1 (en) * 2018-12-20 2020-06-25 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
US11564933B2 (en) 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency
CA3146515A1 (en) 2019-08-09 2021-02-18 Veeran Gowda Kadajji Proliposomal testosterone undecanoate formulations
GB202307501D0 (en) * 2023-05-19 2023-07-05 Lawley Pharmaceuticals Pty Ltd Process for preparing dispensable testosterone cream

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
EP2034961A1 (de) * 2006-06-30 2009-03-18 Gertrud Langhoff Solubilisatformulierungen
EP2146692A1 (en) * 2007-03-19 2010-01-27 Fresenius Kabi Oncology Limited Proliposomal and liposomal compositions
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
US20140309202A1 (en) * 2010-11-30 2014-10-16 Lipocine Inc. High-strength testosterone undecanoate compositions
MA37610B1 (fr) * 2012-05-09 2017-07-31 Univ Western Health Sciences Formulations de testostérone proliposomales

Also Published As

Publication number Publication date
EP3399965A1 (en) 2018-11-14
US20190248830A1 (en) 2019-08-15
JP2019501199A (ja) 2019-01-17
EP3399965A4 (en) 2019-08-21
WO2017120592A1 (en) 2017-07-13
CN108601736A (zh) 2018-09-28

Similar Documents

Publication Publication Date Title
KR20180101452A (ko) 프로리포솜성 테스토스테론 운데카노에이트 제제
EP2763663B1 (en) Pharmaceutical compositions comprising 40-o-(2-hydroxy)ethyl-rapamycin
JP6356215B2 (ja) エベロリムスを含む医薬組成物
EP3636283A1 (en) Solid dosage forms of palbociclib
US20050249799A1 (en) Polymeric drug delivery system for hydrophobic drugs
JP2003504331A (ja) フェノフィブレート含有医薬組成物およびこれを調製するための方法
JP6468661B2 (ja) 遅延放出システアミンビーズ処方、ならびにその作製方法および使用方法
EP3691612B1 (en) High-strength oral taxane compositions and methods
KR102300335B1 (ko) 아프레피탄트의 경구용 조성물
JP2019163327A (ja) 三種混合製剤
CN117693333A (zh) 一种低服用剂量高药物暴露量的索拉非尼或多纳非尼口服制剂及其应用
WO2011096953A1 (en) Oral antidepressant formulation with reduced excipient load
CN101647782A (zh) 长春西汀口服自微乳化微丸及其制备和应用
EP3582778B1 (en) Compositions of gallium (iii) complexes for oral administration
US20250325517A1 (en) Oral dosage forms of elraglusib
TW201811336A (zh) 前體脂質體十一酸睪固酮調配物
HK1259799A1 (en) Proliposomal testosterone undecanoate formulations
TWI867026B (zh) 前體脂質體十一酸睪固酮調配物
WO2025122074A1 (en) Low dose riociguat compositions
HK1212899B (en) Pharmaceutical compositions comprising everolimus
HK1196567A (en) Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin
HK1196567B (en) Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin
JPWO1996019239A1 (ja) 溶解性及び吸収性が向上した固体組成物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180803

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid